$104 Million is the total value of Opus Point Partners Management, LLC's 43 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GILD | Exit | GILEAD SCIENCES INC | $0 | – | -3,282 | -100.0% | -0.23% | – |
| FLDM | Exit | FLUIDIGM CORP DEL | $0 | – | -45,000 | -100.0% | -0.28% | – |
| KPTI | Exit | KARYOPHARM THERAPEUTICS INC | $0 | – | -49,500 | -100.0% | -0.34% | – |
| PSDV | Exit | PSIVIDA CORP | $0 | – | -180,000 | -100.0% | -0.37% | – |
| RXDX | Exit | IGNYTA INC | $0 | – | -81,000 | -100.0% | -0.42% | – |
| DRNA | Exit | DICERNA PHARMACEUTICALS INC | $0 | – | -108,000 | -100.0% | -0.45% | – |
| ZGNX | Exit | ZOGENIX INC | $0 | – | -68,130 | -100.0% | -0.49% | – |
| MACK | Exit | MERRIMACK PHARMACEUTICALS IN | $0 | – | -90,000 | -100.0% | -0.58% | – |
| FLML | Exit | FLAMEL TECHNOLOGIES SAsponsored adr | $0 | – | -69,109 | -100.0% | -0.59% | – |
| ACHN | Exit | ACHILLION PHARMACEUTICALS IN | $0 | – | -99,000 | -100.0% | -0.59% | – |
| ONCE | Exit | SPARK THERAPEUTICS INC | $0 | – | -31,500 | -100.0% | -0.72% | – |
| LOXO | Exit | LOXO ONCOLOGY INC | $0 | – | -36,000 | -100.0% | -0.76% | – |
| CLVS | Exit | CLOVIS ONCOLOGY INC | $0 | – | -75,000 | -100.0% | -1.11% | – |
| VCEL | Exit | VERICEL CORP | $0 | – | -298,941 | -100.0% | -1.35% | – |
| PCRX | Exit | PACIRA PHARMACEUTICALS INC | $0 | – | -35,110 | -100.0% | -1.44% | – |
| EPZM | Exit | EPIZYME INC | $0 | – | -189,564 | -100.0% | -1.78% | – |
| BIB | Exit | PROSHARES TR | $0 | – | -64,462 | -100.0% | -2.04% | – |
| IWM | Exit | ISHARES TRput | $0 | – | -200,000 | -100.0% | -17.10% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-08-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| METTLER-TOLEDO INTL CMN | 20 | Q3 2019 | 4.7% |
| ALNYLAM PHARMACEUTICALS, INC. CMN | 20 | Q3 2019 | 5.0% |
| VERTEX PHARMACEUTICALS INC CMN | 20 | Q3 2019 | 4.0% |
| ILLUMINA, INC. CMN | 20 | Q3 2019 | 4.4% |
| SEATTLE GENETICS, INC. CMN | 20 | Q3 2019 | 4.0% |
| ALEXION PHARMACEUTICALS INC CMN | 20 | Q3 2019 | 4.3% |
| INCYTE CORPORATION CMN | 20 | Q3 2019 | 4.4% |
| NEKTAR THERAPEUTICS CMN | 20 | Q3 2019 | 4.9% |
| REGENERON PHARMACEUTICALS | 20 | Q3 2019 | 3.8% |
| CELGENE CORPORATION CMN | 20 | Q3 2019 | 3.8% |
View Opus Point Partners Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-11-14 |
| 13F-HR | 2019-08-14 |
| 13F-HR | 2019-05-15 |
| 13F-HR | 2019-02-14 |
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| 13F-HR | 2018-05-15 |
| 13F-HR | 2018-02-14 |
| 13F-HR/A | 2017-11-17 |
| 13F-HR | 2017-11-14 |
View Opus Point Partners Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.